Yesterday, Avidity Biosciences announced a definitive agreement to be acquired by Novartis. The transaction includes Avidity’s late-stage programs, including delpacibart zotadirsen (del-zota) for Duchenne.
According to Avidity’s announcement, the company and Novartis intend to keep ongoing studies running smoothly and plan for a seamless transition of programs. The acquisition is expected to close in the first half of 2026, and until that time, Avidity will continue to operate independently.
“We at PPMD congratulate Avidity Biosciences on this significant development, a move that signals exciting momentum for the Duchenne community,” said PPMD CEO Katherine Beaverson, MS. “We look forward to collaborating with Novartis and Avidity to continue to advance research, accelerate therapeutic development, and engage our community meaningfully. Most importantly, we remain committed to ensuring that scientific progress translates into lasting positive impacts and access for families living with Duchenne.”
PPMD will continue to follow this development closely.
Read Avidity’s press release here, and the company’s letter to the community here.
The post Avidity Biosciences to be Acquired by Novartis appeared first on Parent Project Muscular Dystrophy.